« Return to News | CROs/Service Providers

RPS to Acquire Paramax for $1M

Thursday, April 2, 2009 04:00 PM

ReSearch Pharmaceutical Services (RPS) has entered into an agreement to acquire Chinese contract research organization (CRO) Paramax International for $1 million in cash and 530,973 shares of RPS common stock.

The deal, expected to close in late May, will expand RPS’ capabilities in the Asian market by serving as the company’s Asian base of operations. Paramax is headquartered in Beijing, China, with an operations office in Shanghai.

“The acquisition of Paramax will be a key event in the expansion of our existing operations for providing globally integrated clinical research services. The capabilities that the management and staff of Paramax will bring to RPS are essential to meeting our objective of providing innovative, integrated, cost-effective drug development solutions in support of our customer’s product development portfolios,” said RPS CEO Dan Perlman in a company statement.

This latest acquisition is one of several global deals the CRO has made in the past few months. Late last year, RPS acquired three small European CROs.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.